Publication details
Registr FAR NHL a humorální aktivace
| Title in English | Registry FAR NHL and humoral activation |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.kardiologickarevue.cz/casopisy/kardiologicka-revue/2020-2-20/registr-far-nhl-a-humoralni-aktivace-123004 |
| Keywords | chronic heart failure; humoral activation; registry FAR NHL; AHEAD score; prognosis |
| Description | The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with chronic heart failure (CHF) and is focused on pharmacology and humoral activation. It has included 1100 patients, the most frequent etiology of CHF was ischemic heart disease 49.7%. Routine biochemistry and NT-proBNP was evaluated in all patients. Novel humoral substances and markers of oxidative stress: copeptin, MR-proadrenomedullin (MR-proADM), pentraxin (PTX3), galectin3, soluble lectin-like oxidized LDL receptor-1 (sLOX-1) and 3-Nitrotyrosin (3-NT) were measured in a part of study population. Primary endpoint after 1 year follow-up was: death or hospitalization for decompensation of HF or heart transplantation (HTX) or LVAD implantation. More than 50% of patients with stable CHF showed a level of NT-proBNP higher than 600 pg/ml. The level of NT-proBNP was increasing with NYHA class. Patients without primary endpoint (death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation) were assigned as group A, those with the primary endpoint as group B. There were statistically significant differences between the groups in the levels of copeptin, MR-proADM and PTX3 (p <0.001 for all substances). There were no differences in the levels of other substances: galectin3, NGAL, sLOX-1 a 3-NT. When evaluating comorbidities using the AHEAD score, patients with a higher AHEAD score (more comorbidities) achieved the primary endpoint more often. For both humoral agents: copeptin and MR-proADM, there was statistically significant significance for achieving the primary endpoint of patients with lower AHEAD scores (p <0.006 and p <0.003), however, neither agent showed significant predictive value in patients with higher AHEAD scores. Higher levels of the new humoral agents copeptin and MR-proADM could differentiate CHF patients at higher risk of adverse events. The predictive value of these agents is also affected by the patient's comorbidities as assessed by the AHEAD score. New humoral agents could thus have additive value to already traditional and routinely used natriuretic peptides. |